Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ejmCCfbwocfatDrNOsry

  ADVERTISEMENT  
February 5, 2013News for the transfusion medicine and cellular therapy community

  Top Story 
 
  • Study supports link between blood type and clot risk
    People with the AB blood type face a 4% greater risk than people with blood type O of developing blood clots in the veins, according to a study in the Canadian Medical Association Journal. People with Factor V Leiden and a clot-promoting prothrombin genetic mutation had clotting risks that were seven and 11 times greater, respectively, than for people without. Researchers said ABO blood typing should be part of all risk-screening protocols. Time.com/Healthland blog (2/4) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Variety is the spice of life.
That's why Quotient sources cells from US, Europe and Asia for its new to the market antibody screens and ID panels, helping you rule out and rule in antibodies. GPOs must like variety too, because Quotient has new contracts with Premier, Amerinet and GSA, saving you money. Find out how the one company focused on manual testing can serve you in 2013 and beyond.

  Science & Health 
  • Iron drug could reduce need for erythropoietin agents
    Soluble ferric pyrophosphate, Rockwell Medical's iron deficiency drug candidate for patients on hemodialysis, lowered the need for erythropoietin stimulating agents by 37% in a study. The drug is in trials to support an FDA application. Reuters (2/4) LinkedInFacebookTwitterEmail this Story
 
  • StemEx lowers mortality rate in patients with blood cancers
    Gamida Cell said a late-stage clinical trial found its allogeneic stem cell treatment, StemEx, can reduce mortality rates among leukemia and lymphoma patients. The death rate 100 days after StemEx treatment was 15.8%, compared with 24.5% for those treated with two double cord umbilical blood transplants. Globes (Israel) (2/4) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  Industry News & Practice 
  • Teleflex, Ivera sign supply deals with hospital GPO
    Teleflex has received a contract from HealthTrust to provide the hospital group purchasing organization with its Weck line of ligation systems. Separately, Ivera Medical has struck a deal to supply HealthTrust with its Curos Port Protector to prevent catheter-related bloodstream infections and bacterial contamination. MassDevice.com (Boston) (2/4) LinkedInFacebookTwitterEmail this Story
  • BioSante sells GVAX vaccines to Aduro BioTech
    Aduro BioTech agreed to pay $1 million upfront to purchase BioSante Pharmaceuticals' GVAX assets, including vaccines, cell lines and intellectual property. Aduro previously licensed the rights to the GVAX pancreatic and prostate cancer vaccines. The new deal also covers vaccines for multiple myeloma, colon cancer and breast cancer. RTT News (2/4) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • FDA OKs MRI device as companion Dx for iron overload drug
    Resonance Health has received the FDA's OK for its FerriScan R2-MRI system to be sold as a companion diagnostic for Novartis drug Exjade, which is used to treat iron overload in patients suffering from genetic blood disorders. The device is intended to help pinpoint which patients with nontransfusion-dependent thalassemia would best benefit from the drug. AuntMinnie.com (free registration) (2/4) LinkedInFacebookTwitterEmail this Story
  • HHS: Cutting outdated Medicare rules could save $676M yearly
    HHS proposed eliminating some outdated Medicare regulations to save health care providers and hospitals about $3.4 billion in five years, or $676 million a year. "By eliminating outdated or overly burdensome requirements, hospitals and health care professionals can focus on treating patients," HHS Secretary Kathleen Sebelius said. Reuters (2/4) LinkedInFacebookTwitterEmail this Story
  Association News 
  • Tomorrow's AABB audioconference to focus on management of adverse events
    Tomorrow's AABB audioconference will examine the blood center's role in managing adverse events. In particular, the session will discuss the pathophysiology, identification, management and prevention of various acute transfusion reactions. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
Director, Regional Technical Services at Community Blood BankUnited Blood ServicesUS - NV - Las Vegas
Director of Reference & TransfusionCarter BloodcareUS - TX - Bedford
CLINICAL LABORATORY SCIENTISTBlood Centers of the PacificUS - CA - San Francisco
Click here to view more job listings.

  SmartQuote 
Failure changes for the better, success for the worse."
--Seneca the Younger,
Roman philosopher, statesman and playwright


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Jennifer Garfinkel

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information